Neurona Therapeutics is a technology company.
Neurona Therapeutics has raised $144.0M across 2 funding rounds.
Neurona Therapeutics has raised $144.0M in total across 2 funding rounds.
Neurona Therapeutics has raised $144.0M in total across 2 funding rounds.
Neurona Therapeutics's investors include BoxOne Ventures, Iaso Ventures, Ray Muzyka, Canaan Partners, Merian Ventures, Pritzker Group.
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf neural cell therapies to treat chronic neurological disorders by repairing damaged neural circuits, replacing affected cells, and restoring electrical balance in the nervous system.[1][2][3][5] Headquartered in South San Francisco, California, with around 104 employees, it targets conditions like epilepsy through single-dose curative approaches and has received FDA fast-track designation for one therapy to accelerate regulatory approval.[1][4] The company serves patients with severe nervous system diseases, addressing unmet needs in neural repair where traditional treatments fall short, and demonstrates growth through clinical advancement and a strong workplace culture, with 79% of employees rating it as a great place to work.[4]
Founded in 2008 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics emerged from research into neural stem cell therapies, led by scientific pioneers like Arnold Kriegstein from UC San Francisco, who noted consistent patient outcomes across trial sites.[1][3] The idea stemmed from advances in understanding neural progenitor cells' ability to integrate into brain circuits, evolving from preclinical work to a clinical-stage focus on allogeneic therapies that avoid patient-specific manufacturing.[2][5] Early traction included building a patent portfolio and progressing to human trials, culminating in FDA fast-track status last year for its lead candidate, marking a pivotal shift toward potential market approval.[1]
Neurona rides the wave of cell and gene therapy expansion in neurology, where regenerative medicine addresses root causes of intractable diseases like drug-resistant epilepsy amid a $10B+ neurotherapeutics market.[1][2] Timing aligns with maturing stem cell tech, FDA incentives like fast-track status, and post-pandemic biotech investment resurgence, favoring scalable allogeneic models over costly personalized ones.[1] It influences the ecosystem by pioneering neural integration data, potentially unlocking treatments for Alzheimer's or Parkinson's, while fostering South San Francisco's biotech hub through collaborations with academic leaders like UCSF.[1][3][4]
Neurona's path forward hinges on Phase 2/3 trial readouts and regulatory milestones, with its lead asset poised for approval in the next 2-3 years given fast-track momentum, potentially delivering first-in-class epilepsy therapy.[1] Rising demand for curative neurotherapies, AI-driven trial design, and manufacturing scale-up trends will propel growth, expanding to broader indications like movement disorders. As it evolves, Neurona could redefine neural repair, cementing its role from clinical innovator to commercial leader in biotech's regenerative frontier—transforming hope into reality for millions with nervous system diseases.[1][2][5]
Neurona Therapeutics has raised $144.0M across 2 funding rounds. Most recently, it raised $120.0M Series E in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $120.0M Series E | BoxOne Ventures, Iaso Ventures, Ray Muzyka | |
| Nov 1, 2015 | $24.0M Series A | Canaan Partners, Merian Ventures, Pritzker Group |